29 July 2021 | Uncategorized
Podsumowanie subskrypcji akcji zwykłych na okaziciela serii D Celon Pharma S.A.
Warning: Invalid argument supplied for foreach() in /usr/home/sniznik/domains/celonpharma.com/public_html/wp-content/themes/celon/template-front-page.php on line 56
Celon Pharma S.A. is an integrated pharmaceutical company which conducts advanced research and manufactures modern drugs. The company is also a successful marketing authorisation holder for it products. The drugs we offer help thousands of patients lead a better and longer life.
- Current report 34/2021 – Allocation of D-series sharesAllocation of D-series shares
- Celon Pharma has completed its book – building process. Investors will be taking over all Offered Shares.Celon Pharma has completed its book - building process. Investors will be taking over all Offered Shares.
- Celon Pharma S.A. launches public offering of D-series sharesOn 01 July 2021 Celon Pharma S.A. received the decision on approval of the prospectus by the Polish Financial Supervision Authority and published its prospectus in connection with its public offering of D-series shares (the “Offering”). The maximum price in the Offering was set at PLN 45 per share. The Company intends to issue up to 6,000,000 shares and obtain EUR 60 million to finance development of its clinical pipeline and for other corporate purposes, over the course of the next two years.
Research and development
We create innovative drugs, that will change the lives of patients globally
We are leaders in